January - March 2025, Group • Net sales amounted to SEK 0 thousand (0) • Earnings before tax amounted to SEK -42,321 thousand (-67,781) • Earnings per share before dilution amounted to SEK -1.14 (-2.17) • Cash flow from operating activities amounted to SEK -66,329 thousand (-55,311) • Cash flow from investing activities amounted to SEK -14,701 thousand (-5,149) Amounts in parentheses refer to the year-earlier period. Significant events during the quarter • In January, Xspray Pharma issued an update regarding the process for submitting its updated application to the US Food and Drug Administration (FDA) for Dasynoc®, the company's lead product candidate. The timeline was adjusted as the result of one batch of tablets being identified as aberrant. A new batch of tablets was produced to safeguard the stringent quality requirements and production was resumed. • In January, interim data from a food interaction study with product candidate XS003 nilotinib was presented.